MCID: ADN009
MIFTS: 50

Adenosquamous Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Adenosquamous Carcinoma

MalaCards integrated aliases for Adenosquamous Carcinoma:

Name: Adenosquamous Carcinoma 12 14 69
Mixed Adenocarcinoma and Squamous Carcinoma 12
Adenosquamous Cell Carcinoma 12
Carcinoma, Adenosquamous 42
Carcinoma Adenosquamous 52

Classifications:



External Ids:

Disease Ontology 12 DOID:4830
MeSH 42 D018196
NCIt 47 C3727
SNOMED-CT 64 403902008 59367005
UMLS 69 C0206623

Summaries for Adenosquamous Carcinoma

Disease Ontology : 12 A squamous cell carcinoma that contains squamous cells and gland-like cells.

MalaCards based summary : Adenosquamous Carcinoma, also known as mixed adenocarcinoma and squamous carcinoma, is related to papilloma and gastrointestinal stromal tumor. An important gene associated with Adenosquamous Carcinoma is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are Downstream signaling events of B Cell Receptor (BCR) and MAPK signaling pathway. The drugs Cisplatin and Epoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include cervix, lung and pancreas, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and growth/size/body region

Wikipedia : 72 Adenosquamous carcinoma is a type of cancer that contains two types of cells: squamous cells (thin, flat... more...

Related Diseases for Adenosquamous Carcinoma

Diseases related to Adenosquamous Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 220)
id Related Disease Score Top Affiliating Genes
1 papilloma 30.3 MUC1 MUC4
2 gastrointestinal stromal tumor 29.1 EGFR PDGFRA TP53
3 lung cancer 27.5 EGFR KRAS KRT18 MUC4 PTHLH TP53
4 glassy cell variant cervical adenosquamous carcinoma 12.1
5 endometrial adenosquamous carcinoma 12.1
6 gastric adenosquamous carcinoma 12.1
7 cervical adenosquamous carcinoma 12.0
8 esophageal adenosquamous carcinoma 12.0
9 thymus adenosquamous carcinoma 11.9
10 bartholin's gland adenosquamous carcinoma 11.9
11 ampulla of vater adenosquamous carcinoma 11.8
12 adenosquamous gallbladder carcinoma 11.0
13 adenosquamous colon carcinoma 11.0
14 adenosquamous prostate carcinoma 11.0
15 adenosquamous pancreas carcinoma 11.0
16 adenosquamous bile duct carcinoma 10.8
17 severe pre-eclampsia 10.8 EGFR KRAS
18 subglottis verrucous carcinoma 10.8 EGFR MUC1
19 myeloid/lymphoid neoplasm associated with pdgfra rearrangement 10.8 EGFR MUC1
20 laryngeal neuroendocrine tumor 10.7 KRAS MUC1
21 common bile duct disease 10.7 EGFR KRAS
22 bronchus adenoma 10.7 KRT5 MUC1
23 gastric papillary adenocarcinoma 10.7 KRAS MUC1
24 luminal breast carcinoma 10.7 EGFR MUC1
25 tubular adenocarcinoma 10.7 EGFR KRAS
26 familial periodic paralysis 10.7 KRT5 KRT8
27 bestiality 10.7 MUC1 MUC4
28 congenital hemolytic anemia 10.6 KRT5 KRT8
29 pediatric infratentorial ependymoma 10.6 EGFR TP53
30 gastric tubular adenocarcinoma 10.6 AR EGFR
31 thymic dysplasia 10.6 MUC1 TP63
32 breast myoepithelial neoplasm 10.6 KRAS TP53
33 coloboma of inferior eyelid 10.6 KRAS TP53
34 lipid-cell variant infiltrating bladder urothelial carcinoma 10.6 KRT5 TP53
35 sohval soffer syndrome 10.6 EGFR KRAS MUC1
36 microphthalmia/anophthalmia/coloboma spectrum 10.5 KRAS TP53
37 childhood infratentorial neoplasm 10.5 EGFR TP53
38 camptocormism 10.5 KRT8 TP53
39 adenocarcinoma 10.5
40 small intestine leiomyoma 10.5 KRT5 TP53
41 anal squamous cell carcinoma 10.5 KRT5 TP53
42 fallopian tube squamous cell carcinoma 10.5 KRT5 TP53
43 fallopian tube germ cell cancer 10.5 MUC1 TP63
44 pleural empyema 10.5 MUC1 TP53
45 adenocarcinoma in situ 10.5 KRAS TP53
46 mucoepidermoid esophageal carcinoma 10.5 KRT5 MUC1 MUC4
47 pulmonary embolism and infarction 10.5 AR TP53
48 spindle cell liposarcoma 10.4 KRT8 MUC1
49 epithelioid sarcoma 10.4 MUC1 PTHLH
50 vulvar squamous papilloma 10.4 MUC1 TP63

Graphical network of the top 20 diseases related to Adenosquamous Carcinoma:



Diseases related to Adenosquamous Carcinoma

Symptoms & Phenotypes for Adenosquamous Carcinoma

GenomeRNAi Phenotypes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-153 9.8 KRT5
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-154 9.8 KRT18
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-17 9.8 KRT5 CCT2 KRT18
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-180 9.8 KRT5
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-200 9.8 KRT5
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-33 9.8 KRT18
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-71 9.8 KRT5 KRT18
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-84 9.8 CCT2 KRT18
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-91 9.8 KRT5
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-95 9.8 CCT2
11 Decreased viability GR00055-A-2 9.32 EGFR KRAS MUC1
12 Decreased viability GR00106-A-0 9.32 KRAS
13 Decreased viability GR00221-A-1 9.32 EGFR KRAS
14 Decreased viability GR00221-A-2 9.32 KRAS
15 Decreased viability GR00221-A-4 9.32 EGFR
16 Decreased viability GR00301-A 9.32 KRAS
17 Decreased viability GR00381-A-1 9.32 KRAS

MGI Mouse Phenotypes related to Adenosquamous Carcinoma:

44 (show all 18)
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.22 TP53 TP63 AR EGFR KRAS KRT18
2 digestive/alimentary MP:0005381 10.21 AR EGFR KRAS KRT5 KRT8 PDGFRA
3 cardiovascular system MP:0005385 10.18 AR EGFR KRAS KRT8 PDGFRA PTHLH
4 craniofacial MP:0005382 10.17 AR EGFR KRAS KRT5 PDGFRA PTHLH
5 mortality/aging MP:0010768 10.16 PTHLH TP53 TP63 AR EGFR KRAS
6 embryo MP:0005380 10.15 EGFR KRAS KRT18 KRT8 PDGFRA TP53
7 integument MP:0010771 10.11 AR EGFR KRAS KRT5 PDGFRA PTHLH
8 limbs/digits/tail MP:0005371 10.1 AR EGFR KRAS KRT5 PDGFRA PTHLH
9 endocrine/exocrine gland MP:0005379 10.08 EGFR KRAS PDGFRA PTHLH TP53 TP63
10 liver/biliary system MP:0005370 9.95 AR EGFR KRAS KRT18 KRT8 TP53
11 muscle MP:0005369 9.91 AR EGFR KRAS PDGFRA TP53 TP63
12 neoplasm MP:0002006 9.88 AR EGFR KRAS PDGFRA TP53 TP63
13 no phenotypic analysis MP:0003012 9.85 EGFR KRAS KRT5 PDGFRA TP53 TP63
14 renal/urinary system MP:0005367 9.8 AR EGFR KRAS PDGFRA PTHLH TP53
15 reproductive system MP:0005389 9.76 TP63 AR EGFR KRAS KRT8 PDGFRA
16 pigmentation MP:0001186 9.72 AR EGFR KRAS PDGFRA TP53
17 respiratory system MP:0005388 9.43 EGFR KRAS PDGFRA PTHLH TP53 TP63
18 skeleton MP:0005390 9.17 AR EGFR KRAS PDGFRA PTHLH TP53

Drugs & Therapeutics for Adenosquamous Carcinoma

Drugs for Adenosquamous Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 125)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 15663-27-1 84093 441203 2767
2 Epoetin alfa Phase 4,Phase 3 113427-24-0
3 Hematinics Phase 4,Phase 3
4
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
5
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
6
Gemcitabine Approved Phase 3,Phase 2,Phase 1 95058-81-4 60750
7
Topotecan Approved, Investigational Phase 3,Phase 2,Phase 1 119413-54-6, 123948-87-8 60700
8
Vinblastine Approved Phase 3 865-21-4 13342 241903
9
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
10
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
11
Doxorubicin Approved, Investigational Phase 3,Phase 1 23214-92-8 31703
12
Lenograstim Approved Phase 3,Phase 2,Phase 1 135968-09-1
13
Bleomycin Approved Phase 3 11056-06-7 5360373
14
Fluorouracil Approved Phase 3,Phase 1,Phase 2 51-21-8 3385
15
Ifosfamide Approved Phase 3 3778-73-2 3690
16
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
17
Vindesine Approved Phase 3 59917-39-4, 53643-48-4 40839
18
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2 59-30-3 6037
19
leucovorin Approved, Nutraceutical Phase 3,Phase 2 58-05-9 143 6006
20
Doxil Approved June 1999 Phase 3,Phase 1 31703
21
Tirapazamine Investigational Phase 3,Phase 2,Phase 1 27314-97-2
22 Albumin-Bound Paclitaxel Phase 3,Phase 2,Phase 1
23 Antimitotic Agents Phase 3,Phase 2,Phase 1
24 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
25 Antibodies Phase 3,Phase 2,Phase 1
26 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
27 Immunoglobulins Phase 3,Phase 2,Phase 1
28 insulin Phase 3
29 Insulin, Globin Zinc Phase 3
30 Anti-Infective Agents Phase 3,Phase 2,Phase 1
31 Antimetabolites Phase 3,Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
33 Antiviral Agents Phase 3,Phase 2,Phase 1
34 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
35 topoisomerase I inhibitors Phase 3,Phase 2,Phase 1
36 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
37 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
38 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
39 Endothelial Growth Factors Phase 3,Phase 2,Phase 1
40 Mitogens Phase 3,Phase 2,Phase 1
41 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
42 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
43 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
44 Alkylating Agents Phase 3,Phase 2,Phase 1
45 Antirheumatic Agents Phase 3,Phase 1,Phase 2
46 Dermatologic Agents Phase 3
47 Folic Acid Antagonists Phase 3,Phase 2
48 Isophosphamide mustard Phase 3
49 Mitomycins Phase 3
50 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 105)

id Name Status NCT ID Phase Drugs
1 Epoetin Beta in Treating Anemia in Patients With Cervical Cancer Completed NCT00046969 Phase 4 cisplatin
2 Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix Completed NCT00064077 Phase 3 Cisplatin;Gemcitabine Hydrochloride;Paclitaxel;Topotecan Hydrochloride;Vinorelbine Tartrate
3 Paclitaxel and Cisplatin or Topotecan With or Without Bevacizumab in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00803062 Phase 3 Cisplatin;Paclitaxel;Topotecan Hydrochloride
4 Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer Completed NCT00006011 Phase 3 Doxorubicin Hydrochloride;Cisplatin;Paclitaxel
5 Radiation Therapy and Cisplatin With or Without Epoetin Alfa in Treating Patients With Cervical Cancer and Anemia Completed NCT00017004 Phase 3 Cisplatin
6 Comparison of Three Chemotherapy Regimens in Treating Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer Completed NCT00003945 Phase 3 cisplatin;topotecan hydrochloride
7 Radiation Therapy With or Without Chemotherapy After Surgery in Treating Patients With Stage IB or Stage IIA Cervical Cancer Completed NCT00003209 Phase 3 cisplatin;fluorouracil;ifosfamide;methotrexate;mitomycin C;vinblastine sulfate;vindesine
8 Radiation Therapy or Observation Only in Treating Patients With Endometrial Cancer Who Have Undergone Surgery Completed NCT00002807 Phase 3
9 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3 cisplatin;fluorouracil
10 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3 cisplatin;doxorubicin hydrochloride
11 Comparison of Radiation Therapy With or Without Combination Chemotherapy Following Surgery in Treating Patients With Stage I or Stage II Endometrial Cancer Completed NCT00006027 Phase 3 cisplatin;paclitaxel
12 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3 Cisplatin
13 Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy Recruiting NCT00980954 Phase 3 carboplatin;cisplatin;paclitaxel
14 Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix Active, not recruiting NCT01365156 Phase 3
15 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Active, not recruiting NCT01414608 Phase 3 Carboplatin;Cisplatin;Paclitaxel
16 Chemotherapy Followed By Surgery Vs Radiotherapy Plus Chemotherapy in Patients With Stage IB or II Cervical Cancer Active, not recruiting NCT00039338 Phase 3 cisplatin
17 Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology Terminated NCT00596830 Phase 3 CP-751,871 (Figitumumab);Carboplatin;Paclitaxel;Carboplatin;Paclitaxel
18 Evaluation of Hysterectomy After Chemoradiation Therapy for Stage IB2/II Cervical Cancer Terminated NCT01363466 Phase 3
19 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3 cisplatin
20 Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer Terminated NCT00262821 Phase 3 cisplatin;tirapazamine
21 Cisplatin and Radiation Therapy With or Without Hyperthermia Therapy in Treating Patients With Cervical Cancer Terminated NCT00085631 Phase 3 cisplatin
22 Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer Unknown status NCT00008112 Phase 2 cisplatin
23 Panitumumab, Cisplatin, and Pelvic Radiation Therapy in Treating Patients With Stage IB, Stage II, or Stage III Cervical Cancer Unknown status NCT01158248 Phase 2 cisplatin
24 Paclitaxel and Carboplatin Followed by Cisplatin and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Unknown status NCT00462397 Phase 2 carboplatin;cisplatin;paclitaxel
25 Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix Completed NCT00005965 Phase 2 bryostatin 1;cisplatin
26 Capecitabine in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00039442 Phase 2 Capecitabine
27 Ixabepilone to Treat Cervical Cancer Completed NCT00924066 Phase 2 Ixempra (Ixabepilone (BMS-247550) )
28 Selumetinib in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01011933 Phase 2 Selumetinib
29 Gemcitabine in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00820898 Phase 2 Gemcitabine Hydrochloride
30 ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT00309959 Phase 2 Paclitaxel Albumin-Stabilized Nanoparticle Formulation
31 Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT01132820 Phase 2 Cediranib Maleate
32 Pelvic Exenteration in Treating Patients With Recurrent Cervical Cancer Completed NCT00217633 Phase 2
33 Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer Completed NCT01307631 Phase 2 Akt Inhibitor MK2206
34 Sunitinib Malate in Treating Patients With Uterine Cervical Cancer That is Stage IVB, Recurrent, or Cannot Be Removed By Surgery Completed NCT00389974 Phase 2 sunitinib malate
35 Erlotinib in Treating Patients With Locally Advanced and/or Metastatic Endometrial Cancer Completed NCT00030485 Phase 2 erlotinib hydrochloride
36 Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer Completed NCT00057863 Phase 2 Paclitaxel;Oxaliplatin
37 S9717 Tirapazamine Plus Cisplatin in Treating Patients With Metastatic, Recurrent, or Refractory Cervical Cancer Completed NCT00003369 Phase 2 cisplatin;tirapazamine
38 Letrozole in Treating Women With Recurrent or Metastatic Endometrial Cancer Completed NCT00004251 Phase 2 letrozole
39 Temsirolimus in Treating Patients With Cervical Cancer That Is Recurrent, Locally Advanced, Metastatic, or Cannot Be Removed By Surgery Completed NCT01026792 Phase 2 Temsirolimus
40 Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer Completed NCT01266447 Phase 2 Topotecan Hydrochloride;Veliparib
41 Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer Completed NCT01210222 Phase 2
42 Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus Completed NCT00064025 Phase 2 Medroxyprogesterone
43 Thalidomide in Treating Patients With Recurrent or Persistent Endometrial Cancer Completed NCT00025467 Phase 2 thalidomide
44 Irofulven in Treating Patients With Stage IVB or Recurrent Cervical Cancer Completed NCT00005070 Phase 2 irofulven
45 Interleukin-12 in Treating Patients With Advanced or Recurrent Cancer of the Cervix Completed NCT00003017 Phase 2
46 S9720 Combination Chemotherapy in Treating Patients With Metastatic, Recurrent, or Refractory Endometrial Cancer Completed NCT00003127 Phase 2 amifostine trihydrate;carboplatin;paclitaxel
47 Surgery and Vaccine Therapy in Treating Patients With Early Cervical Cancer Completed NCT00002916 Phase 2
48 Bevacizumab, Radiation Therapy, and Cisplatin in Treating Patients With Previously Untreated Locally Advanced Cervical Cancer Completed NCT00369122 Phase 2 cisplatin
49 Intensity-Modulated Radiation Therapy to the Pelvis With or Without Chemotherapy in Treating Patients With Endometrial Cancer or Cervical Cancer That Has Been Removed By Surgery Completed NCT00331760 Phase 2 cisplatin
50 Temsirolimus in Treating Patients With Metastatic or Locally Advanced Recurrent Endometrial Cancer Completed NCT00072176 Phase 2 temsirolimus

Search NIH Clinical Center for Adenosquamous Carcinoma

Cochrane evidence based reviews: carcinoma, adenosquamous

Genetic Tests for Adenosquamous Carcinoma

Anatomical Context for Adenosquamous Carcinoma

MalaCards organs/tissues related to Adenosquamous Carcinoma:

39
Cervix, Lung, Pancreas, Lymph Node, Breast, Colon, Liver

Publications for Adenosquamous Carcinoma

Articles related to Adenosquamous Carcinoma:

(show top 50) (show all 520)
id Title Authors Year
1
Clinicopathological features and prognosis of gastric adenosquamous carcinoma. ( 28676632 )
2017
2
Recent advances in genomic profiling of adenosquamous carcinoma of the pancreas. ( 28816351 )
2017
3
Clinical implications of the proliferative ability of the squamous component regarding tumor progression of adenosquamous carcinoma of the pancreas: A preliminary report. ( 28784574 )
2017
4
Adenosquamous Carcinoma of the Pancreas Demonstrated on 18F-FDG PET/CT Imaging. ( 28098663 )
2017
5
Clinical outcomes of epidermal growth factor receptor tyrosine kinase inhibitors in recurrent adenosquamous carcinoma of the lung after resection. ( 28123305 )
2017
6
Leptomeningeal metastasis of poorly differentiated uterine cervical adenosquamous carcinoma following reirradiation to metastatic vertebrae: A case report. ( 28489796 )
2017
7
Gastric adenosquamous carcinoma producing granulocyte-colony stimulating factor: a case of a rare malignancy. ( 28493097 )
2017
8
Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. ( 28848104 )
2017
9
CD117 expression in adenosquamous carcinoma. ( 28766737 )
2017
10
Genomic signatures of pancreatic adenosquamous carcinoma (PASC). ( 28722109 )
2017
11
Comparative study of ROR2 and WNT5a expression in squamous/adenosquamous carcinoma and adenocarcinoma of the gallbladder. ( 28465645 )
2017
12
Atypical breast adenosquamous carcinoma following acute myeloid leukemia in a middle-aged woman: A case report. ( 28357109 )
2017
13
Importance of tumor extent in adenosquamous carcinoma of the head and neck: a retrospective cohort study. ( 28412233 )
2017
14
The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma. ( 28397462 )
2017
15
Impact of histological subtype on survival in patients with locally advanced cervical cancer that were treated with definitive radiotherapy: adenocarcinoma/adenosquamous carcinoma versus squamous cell carcinoma. ( 28028992 )
2016
16
Improved survival associated with a balanced structure between adenomatous and squamous components in patients with adenosquamous carcinoma of the lung. ( 27365198 )
2016
17
Primary adenosquamous carcinoma of the liver: a case report. ( 28081592 )
2016
18
Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis. ( 27646608 )
2016
19
Primary Colon Adenosquamous Carcinoma in a Patient With Lynch Syndrome: A New Histologic Subtype Associated With Microsatellite Instability? ( 27422471 )
2016
20
Intraluminal superior vena cava metastasis from adenosquamous carcinoma of the duodenum: A case report. ( 26870254 )
2016
21
The Squamous Cells of Adenosquamous Carcinoma (ASCC) of the Prostate Might Represent a Terminally Differentiated Quiescent Component: Immunohistochemical Evidence From a Case of ASCC With Pleomorphic Giant Tumor Cells. ( 27753662 )
2016
22
A case of adenosquamous carcinoma of the lower bile duct diagnosed preoperatively via transpapillary biopsy. ( 27498940 )
2016
23
Primary adenosquamous carcinoma of the esophagus: an analysis of 39 cases. ( 27867543 )
2016
24
Comment on: Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27793441 )
2016
25
Reply: Prognostic factors and impact of adjuvant therapy on survival in early-stage cervical adenocacinoma and adenosquamous carcinoma after primary radical hysterectomy and pelvic lymphadenectomy. ( 27726945 )
2016
26
Cervical adenosquamous carcinoma with extension to uterine corpus. ( 27306573 )
2016
27
Adenosquamous carcinoma of pancreas: CT and MR imaging features in eight patients, with pathologic correlations and comparison with adenocarcinoma of pancreas. ( 27039322 )
2016
28
Nab-paclitaxel+gemcitabine therapy for adenosquamous carcinoma of the pancreas: an autopsy case. ( 27725467 )
2016
29
Analysis of SEER Adenosquamous Carcinoma Data to Identify Cause Specific Survival Predictors and Socioeconomic Disparities. ( 26838235 )
2016
30
S100P is Overexpressed in Squamous Cell and Adenosquamous Carcinoma Subtypes of Endometrial Cancer and Promotes Cancer Cell Proliferation and Invasion. ( 27918216 )
2016
31
Adenosquamous carcinoma in the biliary tract: association of the proliferative ability of the squamous component with its proportion and tumor progression. ( 28034323 )
2016
32
Is cervical screening preventing adenocarcinoma and adenosquamous carcinoma of the cervix? ( 27096255 )
2016
33
MCM2 and TIP30 are prognostic markers in squamous cell/adenosquamous carcinoma and adenocarcinoma of the gallbladder. ( 27748889 )
2016
34
Adenosquamous carcinoma of the tongue: clinicopathologic study and review of the literature. ( 27456683 )
2016
35
Pulmonary micropapillary-type adenosquamous carcinoma sharing epidermal growth factor receptor mutation in adenocarcinoma and squamous cell carcinoma. ( 28127432 )
2016
36
Prognostic factors and adjuvant therapy on survival in early-stage cervical adenocarcinoma/adenosquamous carcinoma after primary radical surgery: A Taiwanese Gynecologic Oncology Group (TGOG) study. ( 27566027 )
2016
37
Oral adenosquamous carcinoma: Report of a rare entity with a special insight on its histochemistry. ( 27721632 )
2016
38
A Case of Pancreatic Adenosquamous Carcinoma Obstructing the Common Bile and Pancreatic Ducts, Duodenum, and Gastric Outlet. ( 26863381 )
2016
39
Characterization of primary pulmonary adenosquamous carcinoma-associated pleural effusion. ( 26797868 )
2016
40
Primary cutaneous adenosquamous carcinoma of the penis: the first characterization of HPV status in this rare and diagnostically challenging entity with review of glandular carcinomas of the penis. ( 27696488 )
2016
41
Oral Adenosquamous Carcinoma Mimicking a Pyogenic Granuloma: a Challenging Diagnosis. ( 27982195 )
2016
42
Serum carbohydrate antigen 12-5 level enhances the prognostic value in primary adenosquamous carcinoma of the lung: a two-institutional experience. ( 27002010 )
2016
43
(18)F-FDG PET/CT in a case of primary hepatic adenosquamous carcinoma. ( 27033745 )
2016
44
A case of ovarian adenosquamous carcinoma arising from endometrioid adenocarcinoma: a case report and systematic review. ( 27514842 )
2016
45
Adenosquamous Carcinoma of the Head and Neck: A Case-Control Study with Conventional Squamous Cell Carcinoma. ( 27169400 )
2016
46
Adenosquamous Carcinoma of the Duodenum: a Rare Entity. ( 27872539 )
2016
47
Tracking the Clonal Evolution of Adenosquamous Carcinoma, a Rare Variant of Intraductal Papillary Mucinous Neoplasm of the Pancreas. ( 27295533 )
2016
48
Adenosquamous carcinoma arising from a thyroglossal duct cyst: A case report. ( 27073536 )
2016
49
Calvaria and orbital metastases of pulmonary adenosquamous carcinoma in a cat: a diagnostic challenge. ( 25648372 )
2015
50
Primary adenosquamous carcinoma of the liver: a case report and review of the literature. ( 26464738 )
2015

Variations for Adenosquamous Carcinoma

Expression for Adenosquamous Carcinoma

Search GEO for disease gene expression data for Adenosquamous Carcinoma.

Pathways for Adenosquamous Carcinoma

Pathways related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 22)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.55 EGFR KRAS PDGFRA TP53
2 12.51 EGFR KRAS PDGFRA TP53
3
Show member pathways
12.45 EGFR KRAS PDGFRA TP53
4
Show member pathways
12.37 EGFR KRAS PDGFRA TP53
5 12.32 AR EGFR KRAS PDGFRA TP53
6 12.29 KRT18 KRT5 KRT8 MUC1
7
Show member pathways
12.25 EGFR KRAS PDGFRA TP53
8
Show member pathways
12.2 EGFR KRAS MUC1 TP53
9
Show member pathways
12.18 EGFR KRAS PDGFRA TP53
10 12.03 EGFR KRAS PDGFRA TP53 TP63
11
Show member pathways
12.01 EGFR KRAS PDGFRA TP53
12
Show member pathways
11.95 EGFR KRAS PDGFRA
13
Show member pathways
11.86 EGFR KRAS TP53
14 11.86 EGFR TP53 TP63
15 11.85 EGFR KRAS TP53
16 11.75 AR EGFR KRAS TP53
17
Show member pathways
11.73 KRT18 KRT5 KRT8
18 11.47 EGFR KRAS TP53
19 11.3 EGFR KRAS PDGFRA TP53
20 11.25 EGFR PDGFRA TP53
21
Show member pathways
10.93 TP53 TP63
22 10.74 EGFR KRAS PDGFRA TP53

GO Terms for Adenosquamous Carcinoma

Cellular components related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein complex GO:0043234 9.46 AR PDGFRA TP53 TP63
2 keratin filament GO:0045095 9.43 KRT18 KRT5 KRT8
3 cytoplasm GO:0005737 9.4 AR CCT2 EGFR KRAS KRT18 KRT5
4 nuclear chromatin GO:0000790 9.26 AR MUC1 TP53 TP63

Biological processes related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

(show all 14)
id Name GO ID Score Top Affiliating Genes
1 viral process GO:0016032 9.83 KRT18 KRT8 PDGFRA TP53
2 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.69 KRAS MUC1 MUC4
3 cornification GO:0070268 9.65 KRT18 KRT5 KRT8
4 positive regulation of cell proliferation GO:0008284 9.65 AR EGFR KRAS PDGFRA PTHLH
5 phosphatidylinositol-mediated signaling GO:0048015 9.63 EGFR PDGFRA TP53
6 female pregnancy GO:0007565 9.58 KRAS MUC1 PTHLH
7 response to X-ray GO:0010165 9.54 TP53 TP63
8 prostate gland development GO:0030850 9.49 AR TP63
9 hepatocyte apoptotic process GO:0097284 9.43 KRT18 KRT8
10 Leydig cell differentiation GO:0033327 9.37 AR PDGFRA
11 mitotic G1 DNA damage checkpoint GO:0031571 9.32 TP53 TP63
12 epidermis development GO:0008544 9.26 EGFR KRT5 PTHLH TP63
13 morphogenesis of an epithelial fold GO:0060571 9.16 AR EGFR
14 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 8.8 MUC1 TP53 TP63

Molecular functions related to Adenosquamous Carcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.46 AR EGFR TP53 TP63
2 p53 binding GO:0002039 9.13 MUC1 TP53 TP63
3 scaffold protein binding GO:0097110 8.8 KRT18 KRT5 KRT8

Sources for Adenosquamous Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....